Financing Innovation Across the Lifecycle

Session details:

• How venture, structured equity, pharma-backed funds, and hybrid models differ in control, risk tolerance, and deal expectations across development stages
• Matching capital strategy to asset maturity—from platform science to single-asset programs—to avoid misalignment that undermines value
• Using creative financing structures (options, tranches, co-investment) as a competitive advantage in crowded deal processes